Francois Valencony started his career in Chicago, IL for Schneider Electric, supporting several acquisitions and growth projects for the North American and South American divisions until 2000. He then actively participated in the development of a start-up software company in London, UK, subsequently acquired by Descartes group. François has been working for Institut Mérieux since 2003, leading several transactions within the diagnostic and biotech business areas, including global out-licensing agreements and acquisitions. Operational responsibilities included the set-up of the first research center of bioMérieux in China and the management of five vaccine programs. Francois is currently General Manager of Mérieux Développement and President of MxD North America. François graduated from HEC in Paris and holds a Master Degree from CEMS in Köln, Germany
Francois Valencony currently serves as board member of:
He is also Board Observer of Twist Bioscience.
Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating at a French/US research program on HIV at Davis University in California, she joined Transgene, an affiliate of Institut Mérieux focusing on immunotherapy, in 1994 where she was in charge of several projects focusing on HIV and Cardiovascular areas until 2000. She then led a spin-off project in cardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capital firm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US.Valérie joined Mérieux Développement as a Partner in January 2010. Valérie received her PhD in Pharmacology from the University of Marseille and . She holds a degree in Hematology and a B.Sc. in Biochemistry-Immunology from the University of Marseille.
Valerie Calenda currently serves as board member of:
Thierry Chignon has more than 25 years of experience in Quality Assurance, Regulatory Affairs, Clinical Trials with particular focus on the medical device sector, including a first experience as Head Pharmacist with Institut Mérieux (10 years).As Director with Quintiles Consulting, between 1997 and 2006, he defined and participated in the implementation of business development strategies for innovative products in Europe. Thierry also worked for 5 years as an expert of the Commission of the European Union drafting Guidelines and Regulations for medical devices. He has chaired standardization working groups in CEN and ISO, as well as a Eucomed Task Force on Tissue engineering.In 2006, Thierry joined Matignon Investissement to raise and deploy the first French fund dedicated to European medical technologies (Matignon Technologies II, 80M€). After several positive exits (trade sale and IPOs), Thierry joined Mérieux Développement in 2014. Thierry holds a Pharmacy Degree, PharmD, a Master Degree from IEP Paris (Sciences Politiques), and an executive MBA from HEC Paris.
Thierry currently serves as Board member of:
Jean-François holds a Phd in Pharmacy and graduated from ESSEC in Paris. He started his career with Pasteur-Mérieux (now Sanofi-Pasteur), the leading global vaccine manufacturer, as Southeast Asia Marketing Manager. Then Joining bioMérieux he developed the company’s initial strategy in Food Safety and Quality services, leading to the investment in Silliker (now Mérieux NutriSciences). Later, he managed Commercial and Business Development operations for bioMérieux Industry, a business Unit of bioMérieux. He then served as Principal at Mercer Management Consulting (now Oliver Wyman), a strategy and management consulting firm, doing extensive work in the fields of sales force effectiveness, operational optimization and growth strategy. Prior to joining Mérieux Developpement, he served as Senior Vice-President at Mérieux NutriSciences, in charge of Strategy, M&A activities and overseeing operations in various geographical zones.
Jean-Francois Billet is currently Board Member of:
Quentin joined Mérieux Développement in 2011, and spent 5 years in the Lyon office of Mérieux Développement.
Quentin is now Regional Investment Manager and is working on the sourcing, evaluation, and diligence of Mérieux Développement investments. He is based in Paris.
Prior to joining Mérieux Développement, Quentin interned at the Martin Maurel private bank as a financial analyst.
Quentin has a Master in Finance and Management from the Reims Business School, and a "European Business Management" license from the University of Coventry (England).
Alix Sipahi - de Saint Etienne joined Mérieux Développement in 2014. After 2 years experience in recruitment in Paris, she joined the educational travel company Worldstrides in 2007 in Boston as a senior overseas operations coordinator until 2014.
Alix holds a Master's degree in Social and Economic Sciences from the Institut Catholique de Paris, including a study abroad program at University of Connecticut. She is currently pursuing an MBA in Finance at Northeastern University.
Dan Fero started his career in venture and growth capital investing with Merieux Developpement in 2016.
Prior to joining the Merieux Developpement team, Dan spent five years in L.E.K. Consulting’s Boston office specialized in the life sciences practice. In that role he served as a strategic advisor to a broad range of corporate clients and life science investors developing deep expertise in corporate strategy and transaction support. Dan has also served as the senior political advisor to two members of the U.S. House of Representatives.
Dan was awarded a Ph.D. in Biomedical Sciences from the University of California, San Diego where he studied the cell signaling basis and engineering applications of Eph receptor signaling. He also holds a Bachelor of Arts degree in Biology from Rhode Island College.
He is Board Observer of Xeris Pharmaceuticals
Senior Business Analyst
Benoit Pierret joined Mérieux Développement in August 2016.
For more than 5 years, he was previously Corporate Finance Manager at Jacquet Metal Services leading various transactions in Europe and North America. Benoit started his career in the field of M&A advisory at Ricol Lasteyrie (member of Ernst&Young), a Paris based consulting firm.
Benoit is a chemical engineer graduated from CPE Lyon and holds a Master in Strategy and Management of International Business from the ESSEC Business School. He also graduated from the ESSEC Chair of Therapeutic Innovation.